Abstract 1650P
Background
AA-P is currently the first-line and second-line treatment in pts with mCRPC. PARP inhibitors plus AA-P has the potential to enhance the anti-tumour activity of abiraterone. In this study, we aimed to evaluate the PARP inhibitor fuzuloparib in combination with AA-P in mCRPC pts.
Methods
This was a 3+3 dose escalation and expansion study in mCRPC pts who had not received prior novel hormonal agents. Eligible pts received fuzuloparib (at escalating doses of 100 and 150 mg BID) for 5 days, followed by fuzuloparib plus AA-P (abiraterone acetate 1000 mg QD, prednisone 5 mg BID) in 28-day treatment cycles. Dose limiting toxicities (DLTs) were observed during the monotherapy and first treatment cycle. Dose expansion started with Group A receiving fuzuloparib at the higher tolerated dose for 5 days and Group B receiving AA-P for 5 days, followed by combination therapies in both groups. Primary objectives were pharmacokinetics and safety.
Results
As of July 20, 2023, 39 pts were enrolled (median follow-up time, 23.2 mo [range, 3.9-44.3]), including 3 in the fuzuloparib 100 mg cohort and 36 in the fuzuloparib 150 mg cohort. No obvious drug-drug interaction was observed with fuzuloparib at 150 mg (n = 36). The combination therapy did not affect exposure (Cmax and AUCss) to abiraterone and had limited effect on exposure to fuzuloparib. There were no DLTs identified. Treatment-related adverse events (TRAEs) occurred in 36 (92.3%) pts, of which 20 (51.3%) reported grade >=3 TRAEs. The most common TRAEs were anaemia (53.8%; grade >=3, 17.9%) and decreased weight (25.6%; grade >=3, 2.6%). There were no unexpected TRAEs or TRAEs leading to death. At Week 12, 28 (71.8%) pts had >=50% reduction in prostate-specific antigen (PSA) from baseline. The maximum reduction in PSA exceeded 50% for 31 (79.5%) pts and 90% for 24 (61.5%) pts. ORR was 60% in pts with measurable lesions. Median PSA PFS was 19.4 mo (95% CI, 11.27-22.76), median rPFS was 27.9 mo (95% CI, 14.0-not reached [NR]), and median DoR was 31.5 mo (95% CI, 4.57-NR) among all pts.
Conclusions
Fuzuloparib plus AA-P had limited drug-drug interaction. The combination therapy was generally tolerated with acceptable safety profile and showed promising efficacy among mCRPC pts.
Clinical trial identification
NCT04108247.
Editorial acknowledgement
Medical writing support was provided by Xinyu Xie (Jiangsu Hengrui Pharmaceuticals).
Legal entity responsible for the study
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
X. Zhou, D. Zhang, C. Yang: Financial Interests, Personal, Full or part-time Employment: Jiangsu Hengrui Pharmaceuticals. All other authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11